Anna D Wagner

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. doi request reprint Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer
    Anna Dorothea Wagner
    1Fondation du Centre Pluridisciplinaire d Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Cochrane Database Syst Rev 7:CD008941. 2012
  2. pmc Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial
    Matthias M Dollinger
    Department of Medicine I, Martin Luther University Halle Wittenberg, Germany
    BMC Cancer 10:457. 2010
  3. doi request reprint Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era
    Anna D Wagner
    Multidisciplinary Oncology Center, Lausanne University Hospital, Lausanne, Switzerland
    Curr Opin Oncol 21:381-5. 2009
  4. pmc Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
    A D Wagner
    First Department of Medicine, University Hospital, Halle 06097 Saale, Germany
    Br J Cancer 101:1846-52. 2009
  5. ncbi request reprint [Anti-angiogenic therapies for metastatic colorectal, breast and lung cancer: benefits and risks]
    A D Wagner
    Centre Pluridisciplinaire d Oncologie, CHUV, Lausanne
    Rev Med Suisse 6:1070-3. 2010
  6. ncbi request reprint Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data
    Anna D Wagner
    First Department of Medicine, Coordinating Centre for Clinical Trials, and Institute of Medical Epidemiology, Biostatistics and Informatics, Martin Luther University Halle Wittenberg, Halle Saale, Germany
    J Clin Oncol 24:2903-9. 2006
  7. ncbi request reprint The role of chemotherapy in patients with established gastric cancer
    Anna D Wagner
    First Department of Medicine, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, Halle Saale, Germany
    Best Pract Res Clin Gastroenterol 20:789-99. 2006

Collaborators

Detail Information

Publications7

  1. doi request reprint Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer
    Anna Dorothea Wagner
    1Fondation du Centre Pluridisciplinaire d Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Cochrane Database Syst Rev 7:CD008941. 2012
    ..By contrast, individual trial results in metastatic breast cancer (MBC) are highly variable and their value is controversial...
  2. pmc Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial
    Matthias M Dollinger
    Department of Medicine I, Martin Luther University Halle Wittenberg, Germany
    BMC Cancer 10:457. 2010
    ..The aim of this study was to assess the efficacy of thymostimulin in a phase III trial...
  3. doi request reprint Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era
    Anna D Wagner
    Multidisciplinary Oncology Center, Lausanne University Hospital, Lausanne, Switzerland
    Curr Opin Oncol 21:381-5. 2009
    ..This review summarizes the experience and major recent advances in the development of targeted therapies in advanced gastric cancer...
  4. pmc Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
    A D Wagner
    First Department of Medicine, University Hospital, Halle 06097 Saale, Germany
    Br J Cancer 101:1846-52. 2009
    ..The objective of these trials was to determine response, survival and toxicity separately in patients with bile duct cancer (BDC) and gallbladder cancer (GBC) treated with gemcitabine/oxaliplatin/5-FU chemotherapy...
  5. ncbi request reprint [Anti-angiogenic therapies for metastatic colorectal, breast and lung cancer: benefits and risks]
    A D Wagner
    Centre Pluridisciplinaire d Oncologie, CHUV, Lausanne
    Rev Med Suisse 6:1070-3. 2010
    ..A summary of the data concerning anti-angiogenic therapies in these three cancers is presented including safety information...
  6. ncbi request reprint Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data
    Anna D Wagner
    First Department of Medicine, Coordinating Centre for Clinical Trials, and Institute of Medical Epidemiology, Biostatistics and Informatics, Martin Luther University Halle Wittenberg, Halle Saale, Germany
    J Clin Oncol 24:2903-9. 2006
    ..This systematic review and meta-analysis were performed to assess the efficacy and tolerability of chemotherapy in patients with advanced gastric cancer...
  7. ncbi request reprint The role of chemotherapy in patients with established gastric cancer
    Anna D Wagner
    First Department of Medicine, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, Halle Saale, Germany
    Best Pract Res Clin Gastroenterol 20:789-99. 2006
    ..Neo-adjuvant chemotherapy has the ability to downsize gastric tumours and appears to improve R0-resection rates, but its potential to improve overall survival is still unclear...